Baclofen/naltrexone/sorbitol - Pharnext

Drug Profile

Baclofen/naltrexone/sorbitol - Pharnext

Alternative Names: (RS)-baclofen/D-sorbitol/naltrexone; (RS)-baclofen/naltrexone/D-sorbitol; Baclofen/sorbitol/naltrexone; Naltrexone/baclofen/sorbitol; Naltrexone/sorbitol/baclofen; PXT 3003; PXT-03003; Sorbitol/baclofen/naltrexone; Sorbitol/naltrexone/baclofen

Latest Information Update: 05 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pharnext
  • Class Aminobutyric acids; Analgesics; Antispastics; Cyclopropanes; Morphinans; Muscle relaxants; Small molecules; Sugar alcohols
  • Mechanism of Action GABA B receptor agonists; Opioid receptor antagonists; PMP22 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Charcot-Marie-Tooth disease
  • New Molecular Entity No

Highest Development Phases

  • Phase III Charcot-Marie-Tooth disease

Most Recent Events

  • 18 Sep 2017 Pharnext announces intention to submit marketing approval applications for Charcot-Marie-Tooth disease in the first quarter of 2019
  • 05 Jun 2017 Chemical structure information added
  • 10 May 2017 Pharnext enters into an agreement with Pharnext-Tasly JV to license baclofen/naltrexone/sorbitol in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top